Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria.

MLA

Wu, R. L., et al. “Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria.” New England Journal of Medicine, vol. 387, no. 5, Aug. 2022, pp. 397–407. EBSCOhost, https://doi.org/10.1056/NEJMoa2203067.

APA

Wu, R. L., Idris, A. H., Berkowitz, N. M., Happe, M., Gaudinski, M. R., Buettner, C., Strom, L., Awan, S. F., Holman, L. S. A., Mendoza, F., Gordon, J., Hu, Z., Chagas, A. C., Wang, L. T., Da Silva Pereiral, L., Francica, J. R., Kisalu, N. K., Flynn, B., Shi, W., & Kong, W.-P. (2022). Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria. New England Journal of Medicine, 387(5), 397–407. https://doi.org/10.1056/NEJMoa2203067

Chicago

Wu, R. L., A. H. Idris, N. M. Berkowitz, M. Happe, M. R. Gaudinski, C. Buettner, L. Strom, et al. 2022. “Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria.” New England Journal of Medicine 387 (5): 397–407. doi:10.1056/NEJMoa2203067.